Bristol Myers Squibb hosts conference on oncology advancements in Cyprus

On June 9, 2026, the biopharmaceutical company Bristol Myers Squibb (BMS) held a press conference in Cyprus to discuss improvements in cancer patient care. The event focused on the importance of early diagnosis, interdisciplinary collaboration, and the adoption of modern therapeutic options. Special emphasis was placed on immuno-oncology as a primary method for managing cancer cases. The conference was moderated by Eleni Dimitriou, Oncology Department Director for BMS Greece and Cyprus. Stelios Kareklas, Head of the Pharmaceutical Division of the C.P.O. Costas Papaellinas Group, delivered an opening address. Elisavet Prodromou, General Manager of BMS Greece and Cyprus, stated that innovative therapies are currently essential tools for transforming terminal cancers into manageable chronic conditions. The company highlighted its commitment to research and development aimed at providing equitable patient access while maintaining healthcare system sustainability.